BMS at AHA Scientific Sessions 2021
Intended for U.S. scientific audiences only.
At this year’s American Heart Association (AHA) Scientific Sessions, we’re looking forward to sharing updates from across our robust cardiovascular pipeline and portfolio. We will highlight key research programs that continue to propel discovery of treatment options for patients with cardiovascular disease around the world.
Hear from our CEO, Giovanni Caforio, M.D., about Bristol Myers Squibb’s presence at the AHA Scientific Sessions and the company’s commitment to patients living with cardiovascular disease.
Our Data at AHA 2021
At the AHA Scientific Sessions 2021, Bristol Myers Squibb is presenting data from across our cardiovascular franchise, including Phase 2 data on our Factor XIa inhibitor, expanded data on our established Factor Xa inhibitor and important data that adds to a growing body of evidence for our cardiac myosin modulator.
For more than 60 years, Bristol Myers Squibb has been a trailblazer in the fight against cardiovascular disease; however, despite many advances, cardiovascular disease continues to be the leading cause of death globally. We are determined to fundamentally change how we approach prevention and treatment of cardiovascular disease in the future.
Learn about atrial fibrillation (AFib) and the No Time to Wait campaign, which aims in part to raise awareness about symptoms of the condition and the importance of talking to a healthcare provider.
Our cardiovascular research follows a science-driven pathway approach that delivers scientific innovation across key areas of focus.